The 2025 annual report identifies a commercial imrecoxib API CMO/CDMO project generating RMB 52.8043 million in revenue; this is not total group revenue.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public financial snapshot
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
Period
Currency / basis
Revenue
Net profit
Operating cash flow
Report
FY2025 2025-12-31
CNY PRC Accounting Standards / consolidated
432,732,134.28
64,294,560.52 Net income attributable to shareholders of the listed company
Consolidated group figures are not equivalent to the CRO/CDMO segment.
Reported 2025 parent-attributable net income was CNY 64.2946 million, while the measure excluding nonrecurring items was a loss of CNY 3.2692 million; review both.
Parent-attributable results moved from profit to loss in the first nine months of 2026. The source reports -151.89% year over year; this is not ranked as conventional earnings growth.
2026Q3 (YTD) · Reporting notes
Consolidated group figures are not equivalent to the CRO/CDMO segment.
Reported 2025 parent-attributable net income was CNY 64.2946 million, while the measure excluding nonrecurring items was a loss of CNY 3.2692 million; review both.
Parent-attributable results moved from profit to loss in the first nine months of 2026. The source reports -151.89% year over year; this is not ranked as conventional earnings growth.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
The 2025 annual report identifies a commercial imrecoxib API CMO/CDMO project generating RMB 52.8043 million in revenue; this is not total group revenue.
Listed entity SZSE 301258; financials are consolidated group figures.
Bio-S Pharmaceutical reported that its joint platform with XtalPi, Hangzhou Baijingyao Biotechnology, was unveiled in Shanghai on November 5. The partners described plans to combine AI-driven discovery with experimental validation, drug development, and clinical translation. The November 6 announcement presents an operating strategy and platform milestone, rather than a quantified licensing transaction or validated clinical outcome.
Fresenius signed an exclusive development agreement with WuXi Biologics providing access to up to 37 biosimilar candidates over the next decade. Initial work is expected to focus on polatuzumab vedotin and teprotumumab biosimilars. Fresenius retains selection flexibility and commercialization economics; the candidate count is an option-based opportunity, not 37 approved products.
Biocytogen reported consolidated revenue of RMB1.403 billion, up 49.09%, and attributable net income of RMB312.4 million for the nine months ended September 30, 2026. Attributable net income increased 173.77%. The group combines animal models, research services, and antibody licensing activities. The quarterly filing is unaudited and covers the year-to-date period.
Stand-alone CRO/CDMO segment profit, orders, and comparable project revenue are not fully disclosed separately; they are not equivalent to consolidated group metrics.
